90 students experience bioprinting at Fluicell
We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…
We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…
We invite you to participate in our Capital Markets Day for a look into Fluicell’s development and future…
The liver plays a central role during drug development because of its function in drug metabolization. Having an…
Aktieägarna i Fluicell AB (publ), org. nr 556889-3282, (”Bolaget”) kallas härmed till årsstämma onsdagen den 17 maj 2023…
We at Fluicell have had an exciting start to this year, with advances across all three business areas….
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…
Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…
We look forward to meeting everyone in the tissue engineering and regenerative medicine community in Manchester for TERMIS-EU…